Overview

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Status:
Recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

The presence of IDH mutation is associated with worse survival in patients with myelofibrosis. Moreover IDH mutations are among the most frequently encountered events in MPNs that have progressed to acute myeloid leukemia. Ruxolitinib, a JAK1/2 inhibitor, and enasidenib an IDH2 inhibitor are effective and tolerable treatments for patients with myelofibrosis (MF) and acute myeloid leukemia (AML), respectively. The study team hypothesize that the combination of these agents in patients with MPN with an IDH2 mutation will improve the overall clinical response to therapy.

Phase:

Phase 2

Details

Lead Sponsor:

John Mascarenhas
Michal Bar-Natan

Collaborators:

Celgene Corporation
Incyte Corporation
Myeloproliferative Neoplasms Research Consortium
National Cancer Institute (NCI)
National Institutes of Health (NIH)